Mitral Valve Disease Market Report 2025

This Mitral Valve Disease market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The mitral valve disease market size has grown strongly in recent years. It will grow from $3 billion in 2024 to $3.3 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to patient education initiatives, adequate reimbursement policies and insurance coverage, growing healthcare expenditure, rising awareness and screening efforts, and expanding market presence.

The mitral valve disease market size is expected to see strong growth in the next few years. It will grow to $4.73 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to growing prevalence of mitral valve disease, increasing adoption for minimally invasive techniques, soaring innovations in heart valve surgery, rise venture capital investments, and rising interest of manufacturers. Major trends in the forecast period include technological advancements, advancements in transcatheter technologies, and increasing technological advancements in surgical procedures.

The rising prevalence of vascular heart diseases is expected to drive the growth of the mitral valve disease market in the coming years. Vascular heart diseases refer to a group of conditions that impact the blood vessels supplying the heart or the heart itself. A combination of lifestyle choices, demographic changes, medical conditions, environmental influences, and genetic factors contributes to the increasing incidence of vascular heart diseases. Conditions such as ischemic heart disease and hypertension can indirectly lead to mitral valve disease by affecting the heart's structure and function, resulting in complications involving the mitral valve. For example, in June 2024, the Australian Bureau of Statistics reported that the death rate from cardiovascular disease per 100,000 population increased from 143.7 in 2021 to 148.2 in 2022 for males, according to data from the National Health Survey conducted by the Australian Institute of Health and Welfare. As a result, the growing prevalence of vascular heart diseases is driving the mitral valve disease market.

Key companies in the mitral valve disease market are developing stented tissue valves to meet the rising demand for minimally invasive treatment options. These valves are designed to offer durable and reliable performance, providing an alternative to traditional surgical methods. For example, in April 2024, Medtronic, an Ireland-based healthcare company, introduced the Avalus Ultra valve, an advanced surgical aortic tissue valve aimed at improving ease of use during implantation and long-term patient management. Building on a decade of clinical experience with the original Avalus valve, the Avalus Ultra features a low-profile valve for easier implantation, a PEEK base frame for consistent circularity, and an industry-leading Effective Orifice Area (EOA), which may enhance blood flow. Additionally, it incorporates a radiopaque coil for better visibility during future valve-in-valve procedures.

In July 2024, Edwards Lifesciences, a US-based medical technology company, acquired Innovative Bio Medical Ltd. for an undisclosed amount. This acquisition is aimed at strengthening Edwards Lifesciences' portfolio of transcatheter mitral valve replacement (TMVR) technologies, helping the company better address unmet needs in structural heart disease and supporting long-term growth. Innovative Bio Medical Ltd., a UK-based medical device company, specializes in developing advanced TMVR technologies.

Major companies operating in the mitral valve disease market are Pfizer Inc., Bayer AG, Abbott Laboratories, Novartis AG, Medtronic plc, Boston Scientific Corporation, Edwards Lifesciences, ShockWave Medical Inc., Artivion Inc., TTK Health Care Limited, Braile Biomedica, JenaValve Technology Inc., 4C Medical technologies, Labcor Laboratorios Ltda, CryoLife Inc., Valcare Medical, Affluent Medical, Colibri Heart Valve LLC, Coramaze Technologies, Corcym UK Limited, HighLife Medical, Micro International Devices Inc., Neovasc Inc., Mitralign Inc., Transcatheter Technologies GmbH.

Europe was the largest region in the mitral valve disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mitral valve disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mitral valve disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Mitral valve disease affects the mitral valve, which regulates blood flow between the heart's left atrium and left ventricle. This disorder can cause narrowing or leakage of the valve, disrupting normal blood circulation and leading to symptoms such as breathlessness, fatigue, and irregular heart rhythms. The primary goal in managing mitral valve disease is to maintain proper blood flow through the heart and prevent complications.

Key treatments for mitral valve disease include mitral valve repair, mitral valve replacement, cardiac resynchronization therapy, and mitral valve therapeutics. Mitral valve repair involves surgical or minimally invasive procedures to correct defects or leaks in the mitral valve, aiming to restore its normal function and prevent further health issues. This treatment is used to address conditions such as mitral valve stenosis, mitral valve prolapse, and mitral valve regurgitation, and is administered in settings such as hospitals and ambulatory surgical centers.

The mitral valve disease market research report is one of a series of new reports that provides mitral valve disease market statistics, including the mitral valve disease industry global market size, regional shares, competitors with mitral valve disease market share, detailed mitral valve disease market segments, market trends, and opportunities, and any further data you may need to thrive in the mitral valve disease industry. These mitral valve disease market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The mitral valve disease market includes revenues earned by entities by providing services such as diagnostic imaging, surgical, and interventional procedures, alongside consultation, rehabilitation, and telemedicine services, catering to patient care and research needs. The market value includes the value of related goods sold by the service provider or included within the service offering. The mitral valve disease market also includes sales of valve repair devices, valve replacement devices, imaging and diagnostic tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.